Department of Epidemiology, Faculty of Medicine, Universidad de Los Andes, Santiago, Chile.
Information Technology Services, Development Department, Universidad de O'Higgins, Rancagua, Chile.
Vaccine. 2024 Jul 11;42(18):3851-3856. doi: 10.1016/j.vaccine.2024.05.002. Epub 2024 May 15.
Case-control studies involving test-negative (TN) and syndrome-negative (SN) controls are reliable for evaluating influenza and rotavirus vaccine effectiveness (VE) during a random vaccination process. However, there is no empirical evidence regarding the impact in real-world mass vaccination campaigns against SARS-CoV-2 using TN and SN controls.
To compare in the same population the effectiveness of SARS-CoV-2 vaccination on COVID-19-related hospitalization rates across a cohort design, TN and SN designs.
We conducted an unmatched population-based cohort, TN and SN case-control designs linking data from four data sources (public primary healthcare system, hospitalization registers, epidemiological surveillance systems and the national immunization program) in a Chilean municipality (Rancagua) between March 1, 2021 and August 31, 2021. The outcome was COVID-19-related hospitalization. To ensure sufficient sample size in the unexposed group, completion of follow-up in the cohort design, and sufficient time between vaccination and hospitalization in the case-control design, VE was estimated comparing 8-week periods for each individual.
Among the 191,505 individuals registered in the primary healthcare system of Rancagua in Chile on March 1, 2021; 116,453 met the cohort study's inclusion criteria. Of the 9,471 hospitalizations registered during the study period in the same place, 526 were COVID-19 cases, 108 were TN controls, and 1,628 were SN controls. For any vaccine product, the age- and sex-adjusted vaccine effectiveness comparing fully and nonvaccinated individuals was 67.2 (55.7-76.3) in the cohort design, whereas it was 67.8 (44.1-81.4) and 77.9 (70.2-83.8) in the TN and SN control designs, respectively.
The VE of a COVID-19 vaccination program based on age and risk groups tended to differ across the three observational study designs. The SN case-control design may be an efficient option for evaluating COVID-19 VE in real-world settings.
涉及测试阴性(TN)和综合征阴性(SN)对照的病例对照研究对于在随机接种过程中评估流感和轮状病毒疫苗的有效性(VE)是可靠的。然而,针对使用 TN 和 SN 对照的针对 SARS-CoV-2 的大规模疫苗接种运动,目前尚无关于其影响的经验证据。
在同一人群中,通过队列设计、TN 和 SN 设计比较 SARS-CoV-2 疫苗接种对 COVID-19 相关住院率的有效性。
我们进行了一项未匹配的基于人群的队列、TN 和 SN 病例对照设计,该设计将来自四个数据源(公共初级保健系统、住院登记处、流行病学监测系统和国家免疫计划)的数据链接到智利一个市镇(兰卡瓜),时间为 2021 年 3 月 1 日至 2021 年 8 月 31 日。结果是 COVID-19 相关的住院治疗。为了确保未暴露组的样本量充足、在队列设计中完成随访以及在病例对照设计中疫苗接种和住院之间有足够的时间,针对每个个体的 8 周周期,对 VE 进行了估计。
在智利兰卡瓜的初级保健系统于 2021 年 3 月 1 日登记的 191505 人中;116453 人符合队列研究的纳入标准。在同一时期在同一地点登记的 9471 例住院中,526 例为 COVID-19 病例,108 例为 TN 对照,1628 例为 SN 对照。对于任何疫苗产品,在队列设计中,比较完全接种和未接种个体的年龄和性别调整后的疫苗有效性为 67.2(55.7-76.3),而 TN 和 SN 对照设计中的疫苗有效性分别为 67.8(44.1-81.4)和 77.9(70.2-83.8)。
基于年龄和风险组的 COVID-19 疫苗接种计划的 VE 在三种观察性研究设计中似乎存在差异。SN 病例对照设计可能是评估真实环境中 COVID-19 VE 的有效选择。